Compare First Horizon Corporation Common Stock (FHN) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Roivant Sciences Ltd. Common Shares trades at $33.68 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.3× First Horizon Corporation Common Stock's market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| FHN | ROIV | |
|---|---|---|
Market Cap | $10.79B | $24.99B |
Volume | 8,579,466 | 4,711,562 |
Sector | Financials | Health |
52-Week High | $26.23 | $41.81 |
52-Week Low | $19.94 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $14.10B | $21.25B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
